BioTech Social Media and Updates

Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
SocialApr 27, 2026

Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/d0JNE6pb5x

By Mike Thompson, MD PhD
Uridine Shields Neurons by Activating Mitochondrial K⁺ Channel
SocialApr 27, 2026

Uridine Shields Neurons by Activating Mitochondrial K⁺ Channel

The Protective Effect of Uridine in a Rotenone-Induced Model of Parkinson’s Disease: The Role of the Mitochondrial ATP-Dependent Potassium Channel https://t.co/jBlSlgedWo

By Michael Lustgarten, PhD
Deregulation Accelerates AI Drug Discovery Across Borders
SocialApr 26, 2026

Deregulation Accelerates AI Drug Discovery Across Borders

Two articles were just published in English featuring Insilico and my OpenClaw noticed. Here is an interesting story. In 2017, before going into China, we set up Insilico Korea and I spent a considerable amount of time there trying to...

By Alex Zhavoronkov, PhD
Epigenetic Clocks Predict Lung Cancer Risk Beyond Self‑reports
SocialApr 26, 2026

Epigenetic Clocks Predict Lung Cancer Risk Beyond Self‑reports

New paper: Epigenetic age clocks help predict lung cancer risk & mortality by estimating smoke exposure. Is independent of self-reported smoking history, so people probably lie about it. Clocks could help doctors predict lung cancer risk & decide on...

By David Sinclair, PhD
Blocking Gut “Signal Two” Expands Tregs, Curbs IBD
SocialApr 26, 2026

Blocking Gut “Signal Two” Expands Tregs, Curbs IBD

Blocking immune 'signal two' in the gut expands a specialized regulatory T cell population, suppressing intestinal inflammation and suggesting a new therapeutic approach for inflammatory bowel disease and related autoimmune conditions. immunology

By Phys.org Threads
AI's First Real Test: Designing Drugs at Isomorphic Labs
SocialApr 26, 2026

AI's First Real Test: Designing Drugs at Isomorphic Labs

Isomorphic Labs Is About to Find Out If AI Can Actually Design a Drug https://t.co/vhQTwhIO85

By Shashi Bellamkonda
MIB‑626 NMN Shows Lifespan Boost and New Mechanism
SocialApr 26, 2026

MIB‑626 NMN Shows Lifespan Boost and New Mechanism

1. No living forever 🙈 2. Some MIB-626 (crystaline polymorph, pure NMN) human clinical trial results are in 😀 3. About to resubmit a revised mouse MIB-626 paper with Alice Kane, showing improved health measures + lifespan & a putative new mechanism...

By David Sinclair, PhD
NTLA Set to Unveil First In‑Vivo CRISPR Phase 3 Data
SocialApr 26, 2026

NTLA Set to Unveil First In‑Vivo CRISPR Phase 3 Data

Here is a video of me entering my office tomorrow knowing that $NTLA is about to present the first-ever Phase 3 data of an In Vivo (!) CRISPR Gene Editing Program. Somehow - and after @adamfeuerstein’s🧵👇- I have a feeling...

By Yair Einhorn
Exploring Germany's Emerging Biotech Hubs in Tübingen and Heidelberg
SocialApr 26, 2026

Exploring Germany's Emerging Biotech Hubs in Tübingen and Heidelberg

All this week, I'm in Germany checking out the biotech scene in a couple of university towns: Tübingen and Heidelberg. Tune in.

By Brad Loncar
Missing Controls Cause Silent Bioinformatics Failures
SocialApr 26, 2026

Missing Controls Cause Silent Bioinformatics Failures

1/ Too many bioinformatics analysis crash silently. You think it worked. But the truth? You didn’t include controls. That means: Bad results. Wrong science. https://t.co/UGGDX3PQzz

By Ming Tang
Nesprin‑2 Protein Blocks Heart Cancer, May Aid Other Tumors
SocialApr 26, 2026

Nesprin‑2 Protein Blocks Heart Cancer, May Aid Other Tumors

Wondered why we don’t hear about heart cancer? Contraction-sensing Nesprin-2 protein is discovered to prevent heart cancer By causing cells to pulse (or adding in Nespirin) we might be able to treat cancer in other organs 👏 @ScienceMagazine https://t.co/A8fOuw31N2

By David Sinclair, PhD
Consumer Biotech Poised to Dominate, Telehealth Captures Value
SocialApr 26, 2026

Consumer Biotech Poised to Dominate, Telehealth Captures Value

I’ve said this before: I believe consumer biotech will become the most compelling sub-sector within biotech - without question - and one of the most attractive investment opportunities overall. At its core, this category targets products that slow or reverse aging,...

By Christian Angermayer
Anecdotes Aren’t Data: Call for Rigorous Rapamycin Trials
SocialApr 26, 2026

Anecdotes Aren’t Data: Call for Rigorous Rapamycin Trials

Table updates worth noting 🔎 🔘 @bryan_johnson stopped it 🔘Alan Green died at 80 from hereditary cardiomyopathy 🫀 🔘Misha Blagosklonny died at 63 from cancer 👉These are cases, not data. Instead of adjusting the tally, what we actually need are rigorous human trials. Is rapamycin...

By David Barzilai, MD PhD
Russian Gene Therapy Claims to Extend Life to 150
SocialApr 25, 2026

Russian Gene Therapy Claims to Extend Life to 150

Russian scientist in bombshell ageing drug claim after Putin discussed 'living to 150' The Russian gene-therapy treatment could benefit Putin and his inner circle. https://t.co/dunqBJEPxN https://t.co/sH2GNbRqSs

By David Barzilai, MD PhD
Nanophotonic Chips Finally Make the Proteome Visible
SocialApr 25, 2026

Nanophotonic Chips Finally Make the Proteome Visible

We sequence genomes and map transcriptomes with ease. Why is the proteome still invisible? Proteins are where biology actually happens. But until now, we have lacked the tools to read them at scale. @jendionne and her team are building nanophotonic chips that...

By John Cumbers
GLP‑1 Drugs May Trigger New Restrictive Eating Disorders
SocialApr 25, 2026

GLP‑1 Drugs May Trigger New Restrictive Eating Disorders

"There is also compelling preliminary evidence suggesting that the use of these drugs [GLP-1] could exacerbate and lead to new diagnoses of restrictive eating disorders, including anorexia nervosa." @NEJM today https://t.co/PeTLgyRXiL

By Eric Topol
GLP‑1 Weight Loss Drugs Lower HRV, Raise Heart Rate
SocialApr 25, 2026

GLP‑1 Weight Loss Drugs Lower HRV, Raise Heart Rate

Reducing body weight with GLP-1 agonists isn't a free lunch: negative impacts on HRV, RHR GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons https://t.co/4QNy141TtK

By Michael Lustgarten, PhD
NVO Shows Fewer AEs; LLY Wins on Lower COGS
SocialApr 25, 2026

NVO Shows Fewer AEs; LLY Wins on Lower COGS

The $NVO drug has fewer AEs (based on comparative discontinuation rates) - only real advantage $LLY has here is much lower COGS (small molecule vs poorly absorbed peptide).

By Peter Suzman
Epigenetic Plasticity Enables Precision Targeting of Senescent Cells
SocialApr 25, 2026

Epigenetic Plasticity Enables Precision Targeting of Senescent Cells

Epigenetic regulation of cellular senescence "This review proposes a roadmap for leveraging epigenetic plasticity, offering a precision medicine approach to target specific senescent cell populations and extend health span." https://t.co/UAuBP8WEeR https://t.co/i0XzhPM0NB

By David Barzilai, MD PhD
Advanced Biotech Diagnostics Enable Precise Disease Detection
SocialApr 25, 2026

Advanced Biotech Diagnostics Enable Precise Disease Detection

Accurate Disease Detection with Advanced Biotech Diagnostics by @antgrasso #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/nQIkC2nuzM

By Ron van Loon
Undetected Antibodies Can Undermine Phage Therapy Effectiveness
SocialApr 24, 2026

Undetected Antibodies Can Undermine Phage Therapy Effectiveness

Hidden antibodies in patients can neutralize bacteriophages, limiting the effectiveness of phage therapy for drug-resistant infections and highlighting the need for pre-treatment antibody screening. infectiousdisease

By Phys.org Threads
Targeting iNOS‑IRG1 Binding Offers Precise Anti‑Inflammatory Therapy
SocialApr 24, 2026

Targeting iNOS‑IRG1 Binding Offers Precise Anti‑Inflammatory Therapy

A newly discovered interaction between iNOS and IRG1 proteins directly regulates inflammation, suggesting that targeting their physical binding could offer more precise therapies for Crohn's disease, arthritis, and cardiovascular conditions. immunology

By Phys.org Threads
Invest in Proven Canine Cardiac Reversal Biotech
SocialApr 24, 2026

Invest in Proven Canine Cardiac Reversal Biotech

I co-founded @RejuvenateBio & have enjoyed the science from day one. Cardiac disease reversal in dogs. 3 years of safety data. Zero safety signals. They’ve opened a unique opportunity for the biotech community to invest & secure equity at this early...

By George Church
Finish Vibecoded TUI Editor Before SnapGene Expires
SocialApr 24, 2026

Finish Vibecoded TUI Editor Before SnapGene Expires

I am challenging myself to make enough progress on my vibecoded TUI plasmid editor before my SnapGene subscription expires. Follow allong by simply typing in: pipx install splicecraft into your terminal or check out my github here: https://t.co/3mkWtVqa1T https://t.co/1OZAggXIBT

By Sebastian Cocioba
Nanodrum Beats Identify Bacterial Infections by Sound
SocialApr 24, 2026

Nanodrum Beats Identify Bacterial Infections by Sound

Researchers report that bacterial infections could be diagnosed with sound, using a nanoscale drum kit. Different bacteria play different rhythms on the drum. https://spectrum.ieee.org/soundcell-nanodrums-identify-bacteria-sound

By IEEE Spectrum Threads
Human Genetic Optimization Funding Claim Is Pure Fantasy
SocialApr 24, 2026

Human Genetic Optimization Funding Claim Is Pure Fantasy

From Mother Jones story on polygenic selection and embryo editing plans. Absolutely zero chance that human genetic optimization companies raised $36.5 billion in 2024. This number is fantasy. https://t.co/we6euyIMXv

By Antonio Regalado
Readout LOUD Interview Explores Kelonia and Eli Lilly
SocialApr 24, 2026

Readout LOUD Interview Explores Kelonia and Eli Lilly

Our Readout LOUD interview with @BRobertsVC about Kelonia and $LLY in print form. https://t.co/DsfGxwcvS3 via @statnews

By Adam Feuerstein
Scaling Cheap In‑Vivo Causal Testing for Age‑Related Diseases
SocialApr 24, 2026

Scaling Cheap In‑Vivo Causal Testing for Age‑Related Diseases

AI has made hypothesis generation in bio cheap. Anyone can get an answer to ‘could this play a role in my disease’, but how do we go from ‘could’ to ‘does’? The scarce resource now is causal evidence to test hypotheses...

By Martin Borch Jensen
ER-100 Cleared for Trials; Safety Promising, Translation Uncertain
SocialApr 24, 2026

ER-100 Cleared for Trials; Safety Promising, Translation Uncertain

So far, the data suggest ER-100 should be safe in humans, and the FDA has cleared us to move into clinical trials. Translation from primates to humans is never guaranteed If it doesn’t work as hoped, we’ll learn & improve, just...

By David Sinclair, PhD
Vertical AI Beats Generic Models in Enzyme Engineering
SocialApr 24, 2026

Vertical AI Beats Generic Models in Enzyme Engineering

Foundation models are powerful. They're also generic. And in industrial enzyme engineering, generic doesn't cut it. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK The industrial last mile of...

By John Cumbers
GPT-5 Autonomously Outperforms SOTA Protein Synthesis by 40%
SocialApr 24, 2026

GPT-5 Autonomously Outperforms SOTA Protein Synthesis by 40%

More on our work with @OpenAI where GPT-5 ran our autonomous lab at @Ginkgo and beat state of the art by 40% in cell free protein synthesis 👇

By Jason Kelly
Lilly Slides as FDA Plans Psychedelic Voucher Program
SocialApr 24, 2026

Lilly Slides as FDA Plans Psychedelic Voucher Program

Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics https://t.co/kWvYtFeif0 $LLY - 4% $NVO + 6% $REGN $AMGN $BBOT #biotech

By Ben Fidler
New Psychedelic Trials Target Depression and PTSD
SocialApr 24, 2026

New Psychedelic Trials Target Depression and PTSD

Compass Pathways’ psilocybin (COMP360) for treatment-resistant depression (TRD) Usona Institute’s psilocybin for major depressive disorder (MDD) Otsuka’s methylone (TSND-201) for PTSD

By Julie Holland
GPX4 Inhibitors Eradicate Senescent Tumor Cells, Boost Chemo Efficacy
SocialApr 24, 2026

GPX4 Inhibitors Eradicate Senescent Tumor Cells, Boost Chemo Efficacy

GPX4 inhibitors discovered that kill "zombie" senescent cells from tumors (increased w/ chemoRx) and effective in multiple preclinical models vs cancer, a new potential strategy to pursue in clinical trials https://t.co/lYX7xkI9xF @NatureCellBio https://t.co/mxbjzRQPck

By Eric Topol
Harmony Scales scRNA‑seq Integration Beyond 100 Million Cells
SocialApr 24, 2026

Harmony Scales scRNA‑seq Integration Beyond 100 Million Cells

Harmony is my go-to tool for scRNAseq integtation. Now it sales to >100M cells. https://t.co/4rdXHT8ask https://t.co/SzbC5MnaoU

By Ming Tang
AI-Designed PRMT5 Inhibitor Nominated in UAE
SocialApr 24, 2026

AI-Designed PRMT5 Inhibitor Nominated in UAE

Today marks a historic moment for Insilico and another world's first in AI-powered drug discovery. We nominated the first preclinical/developmental candidate in the UAE. It is also our 30th PCC/DC nominated in the past 5 years. 12 molecules reached clinical...

By Alex Zhavoronkov, PhD
PMVP Poised for Sale After Strong Phase 2 Results
SocialApr 24, 2026

PMVP Poised for Sale After Strong Phase 2 Results

Some movement on $PMVP worth flagging. Strong Phase 2 results, the market gave zero credit. But something is stirring. Board just appointed Laurie Stelzer as Chairman. CFO track record across multiple major pharma buyouts. Clear corporate finance chops. PMVP might be prepping for...

By Dalius – Special Sits
Epigenetic Reset: Once Mocked,
SocialApr 24, 2026

Epigenetic Reset: Once Mocked,

From 2008-2024 I was accused of hyping (a common slur) for suggesting that changes to the epigenome might cause aging and that therapeutics could "allow us to reset the epigenome to a more youthful state." - Oberdoerffer & Sinclair...

By David Sinclair
Former FDA Staffer Cites Political Pressure Blocking Rare‑disease Drug Approval
SocialApr 24, 2026

Former FDA Staffer Cites Political Pressure Blocking Rare‑disease Drug Approval

Former FDA staffer - “I recently left FDA due to the political pressure I was receiving to withhold my recommendation for approval for a drug that was intended for a rare disease. I was part of a review division that...

By Bijan Salehizedah
Start Lifestyle Changes With GLP‑1, Not After Stopping
SocialApr 24, 2026

Start Lifestyle Changes With GLP‑1, Not After Stopping

The GLP-1 weight regain studies everyone is citing have a quiet design flaw: in a lot of those trials, patients were put on a rigid reduced-calorie plan while on the drug, then told to keep following that same rigid plan...

By Kevin Pho, MD
FGF21 Shows Dual Action: Reduces Drinking, Shields Liver
SocialApr 24, 2026

FGF21 Shows Dual Action: Reduces Drinking, Shields Liver

The study validated FGF21-a liver-derived hormone currently in clinical trials for fatty liver disease “as a dual-action therapeutic that both curbs harmful drinking behaviors and protects against alcohol-related liver injury https://t.co/VdPZvQQ9qp

By Liz Parrish
Houston Friday Night: Comedy, Immunization Partnership Celebrate Vaccines
SocialApr 24, 2026

Houston Friday Night: Comedy, Immunization Partnership Celebrate Vaccines

Friday night in HoustonTX I will be there along with The Immunization Partnership and COMEDY INJECTION, VACCINES: 9th Wonder of the World https://t.co/GPSrrB3poV https://t.co/THhFN31ebn

By Peter Hotez
Meta-Analysis Flawed by Mixing Disparate Anti‑amyloid Agents
SocialApr 23, 2026

Meta-Analysis Flawed by Mixing Disparate Anti‑amyloid Agents

A harsh critique of the recent @cochranecollab meta-analysis of the anti-amyloid drugs for Alzheimer's disease https://t.co/EU4JMOVWkV 'These results and their overarching conclusion that “successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in...

By Eric Topol
Scientists Convert pMMR Tumors to Immunotherapy‑Sensitive dMMR
SocialApr 23, 2026

Scientists Convert pMMR Tumors to Immunotherapy‑Sensitive dMMR

For anyone else fried with #AACR26 abstracts, we can now look at them from a different lens...

By Sally Church
Continuous Glucose Monitoring Outperforms Self‑Monitoring in Type 2 Diabetes
SocialApr 23, 2026

Continuous Glucose Monitoring Outperforms Self‑Monitoring in Type 2 Diabetes

A randomized trial of continuous glucose monitoring (CGM) vs self-monitoring for Type 2 diabetes on basal insulin and drug therapies shows superiority of CGM for gluocse regulation https://t.co/XUymGiov1c @TheLancetEndo https://t.co/lcjFDnEG6x

By Eric Topol
Alleged FDA Pressure Removes Study Confirming Long‑term Vaccine Efficacy
SocialApr 23, 2026

Alleged FDA Pressure Removes Study Confirming Long‑term Vaccine Efficacy

Vinay Prasad forced FDA scientists to withdraw a paper from Vaccine, the journal I am co-EIC of, because it showed that COVID vaccines work for everyone 6 months+. This is Gold Standard Science at Marty Makary’s FDA. Setting the Gold...

By Angela Rasmussen
CAR‑T Turnaround: Kelonia’s LLY Deal Signals New Pharma Play
SocialApr 23, 2026

CAR‑T Turnaround: Kelonia’s LLY Deal Signals New Pharma Play

A VERY SPIRITED interview w/ Venrock VC Bryan Roberts re: Kelonia Therapeutics and its $LLY deal on this week's Readout LOUD podcast. A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts https://t.co/600DsE1cBm via @statnews

By Adam Feuerstein
Scalable Hypothesis‑testing Datasets Will Drive Biology’s AI ROI
SocialApr 23, 2026

Scalable Hypothesis‑testing Datasets Will Drive Biology’s AI ROI

Which AI-enabling datasets will bring the biggest ROI in biology? One type will be "ways to confirm hypotheses at scale". @GordianBio is building atlases of how every expressed gene target affects organs suffering diseases of aging.

By Martin Borch Jensen
NIH Director Censors Routine Vaccine Study Over Personal Dislike
SocialApr 23, 2026

NIH Director Censors Routine Vaccine Study Over Personal Dislike

To be clear: @NIHDirector_Jay reportedly took issue with the study design, which is routine for evaluating vaccines post-market. Podcast Jay, who has no expertise in vaccine trials, decided unilaterally he didn’t like it & thus censored results of studies our...

By Angela Rasmussen